IFN-λ1 Displays Various Levels of Antiviral Activity In Vitro in a Select Panel of RNA Viruses

Type III interferons (lambda IFNs) are a quite new, small family of three closely related cytokines with interferon-like activity. Attention to IFN-lambda is mainly focused on direct antiviral activity in which, as with IFN-alpha, viral genome replication is inhibited without the participation of immune system cells. The heterodimeric receptor for lambda interferons is exposed mainly on epithelial cells, which limits its possible action on other cells, thus reducing the likelihood of developing undesirable side effects compared to type I IFN. In this study, we examined the antiviral potential of exogenous human IFN-lambda 1 in cellular models of viral infection. To study the protective effects of IFN-lambda 1, three administration schemes were used: 'preventive' (pretreatment); 'preventive/therapeutic' (pre/post); and 'therapeutic' (post). Three IFN-lambda 1 concentrations (from 10 to 500 ng/mL) were used. We have shown that human IFN-lambda 1 restricts SARS-CoV-2 replication in Vero cells with all three treatment schemes. In addition, we have shown a decrease in the viral loads of CHIKV and IVA with the 'preventive' and 'preventive/therapeutic' regimes. No significant antiviral effect of IFN-lambda 1 against AdV was detected. Our study highlights the potential for using IFN-lambda as a broad-spectrum therapeutic agent against respiratory RNA viruses.

Automated summary

Type III interferons, particularly IFN-lambda, show potential as a broad-spectrum therapeutic agent against respiratory RNA viruses by directly inhibiting viral replication. Their limited impact on non-epithelial cells may reduce undesirable side effects compared to Type I interferons.